ArticleThe Journal of infectious diseases2020
Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 75 citations in OpenAlex.
- An Fc Receptor and IgA Functional Signature Identifies TB Disease in Children Living With HIV.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Article
- Glycosylation profile ofiScience · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- Antibodies in tuberculosis: functional capacity as key determinant.Infection and immunity · 2026Review
- Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.Frontiers in immunology · 2026Review
- ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteria.Cell reports · 2025Article
- Airflow Determines Natural Airborne Transmission of Tuberculosis in a Guinea Pig Model.bioRxiv : the preprint server for biology · 2025Article
- Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1.PLoS pathogens · 2025Article
- Sample-sparing multiplexed antibody Fc biomarker discovery using a reconfigurable integrated microfluidic platform.Lab on a chip · 2025Article
- Sera contributing to mycobacterial growth restrictioniScience · 2025Article
- Impact of different pathogen classes on the serumBBA advances · 2025Article
- Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis.Nature microbiology · 2024Article
- Infection and the Glycome─New Insights into Host Response.ACS infectious diseases · 2024Review
- Antigen specificity shapes antibody functions in tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- GlYcoLISA: antigen-specific and subclass-specific IgG Fc glycosylation analysis based on an immunosorbent assay with an LC-MS readout.Nature protocols · 2024Review
- Age and sex influence antibody profiles associated with tuberculosis progression.Nature microbiology · 2024Article
- Evaluation of serological assays for the diagnosis of childhood tuberculosis disease: a study protocol.BMC infectious diseases · 2024Article
- SLIDE: Significant Latent Factor Interaction Discovery and Exploration across biological domains.Nature methods · 2024Article
- Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMycobacterium tuberculosis remains a global health problem and clinical management is complicated by difficulty in discriminating between latent infection and active disease. While M. tuberculosis-reactive antibody levels are heterogeneous, studies suggest that levels of IgG glycosylation differ between disease states. Here we extend this observation across antibody domains and M. tuberculosis specificities to define changes with the greatest resolving power.
methodsCapillary electrophoretic glycan analysis was performed on bulk non-antigen-specific IgG, bulk Fc domain, bulk Fab domain, and purified protein derivative (PPD)- and Ag85A-specific IgG from subjects with latent (n = 10) and active (n = 20) tuberculosis. PPD-specific isotype/subclass, PPD-specific antibody-dependent phagocytosis, cellular cytotoxicity, and natural killer cell activation were assessed. Discriminatory potentials of antibody features were evaluated individually and by multivariate analysis.
resultsParallel profiling of whole, Fc, and Fab domain-specific IgG glycosylation pointed to enhanced differential glycosylation on the Fc domain. Differential glycosylation was observed across antigen-specific antibody populations. Multivariate modeling highlighted Fc domain glycan species as the top discriminatory features, with combined PPD IgG titers and Fc domain glycans providing the highest classification accuracy.
conclusionsDifferential glycosylation occurs preferentially on the Fc domain, providing significant discriminatory power between different states of M. tuberculosis infection and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.